<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: We examined the role of the phosphatidylinositol-3 kinase (PI3K)/nitric <z:chebi fb="177" ids="25741,29356">oxide</z:chebi> (NO) signaling pathway in low-level vagus nerve stimulation (LLVNS)-mediated inhibition of <z:hpo ids='HP_0005110'>atrial fibrillation</z:hpo> (AF) </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: In 17 pentobarbital anesthetized dogs, bilateral thoracotomies allowed the attachment of electrode catheters to the superior and inferior pulmonary veins and atrial appendages </plain></SENT>
<SENT sid="2" pm="."><plain>Rapid atrial pacing (RAP) was maintained for 6 h </plain></SENT>
<SENT sid="3" pm="."><plain>Each hour, programmed stimulation was used to determine the window of vulnerability (WOV), a measure of AF inducibility, at <z:hpo ids='HP_0000001'>all</z:hpo> sites </plain></SENT>
<SENT sid="4" pm="."><plain>During the last 3 h, RAP was overlapped with right LLVNS (50 % below that which slows the sinus rate) </plain></SENT>
<SENT sid="5" pm="."><plain>In group 1 (n = 7), LLVNS was the only intervention, whereas in groups 2 (n = 6) and 3 (n = 4), the NO synthase inhibitor N (G)-<z:chebi fb="13" ids="29785">nitro</z:chebi>-<z:chebi fb="0" ids="16467,29952">L-arginine</z:chebi> <z:chebi fb="36" ids="29309">methyl</z:chebi> <z:chebi fb="21" ids="35701">ester</z:chebi> (L-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NAME</z:e>) and the PI3K inhibitor <z:chebi fb="0" ids="52289">wortmannin</z:chebi>, respectively, were injected in the right-sided ganglionated plexi (GP) during the last 3 h </plain></SENT>
<SENT sid="6" pm="."><plain>The duration of <z:chebi fb="9" ids="15355">acetylcholine</z:chebi>-induced AF was determined at baseline and at 6 h </plain></SENT>
<SENT sid="7" pm="."><plain>Voltage-sinus rate curves were constructed to assess GP function </plain></SENT>
<SENT sid="8" pm="."><plain>RESULTS: LLVNS significantly decreased the <z:chebi fb="9" ids="15355">acetylcholine</z:chebi>-induced AF duration by 8.2 ± 0.9 min (p &lt; 0.0001) </plain></SENT>
<SENT sid="9" pm="."><plain>Both L-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NAME</z:e> and <z:chebi fb="0" ids="52289">wortmannin</z:chebi> abrogated this effect </plain></SENT>
<SENT sid="10" pm="."><plain>The cumulative WOV (the sum of the individual WOVs) decreased toward baseline with LLVNS (p &lt; 0.0001) </plain></SENT>
<SENT sid="11" pm="."><plain>L-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NAME</z:e> and <z:chebi fb="0" ids="52289">wortmannin</z:chebi> blunted this effect during the fifth (L-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NAME</z:e> only, p &lt; 0.05) and the sixth hour (L-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NAME</z:e> and <z:chebi fb="0" ids="52289">wortmannin</z:chebi>, p &lt; 0.05) </plain></SENT>
<SENT sid="12" pm="."><plain>LLVNS suppressed the ability of GP stimulation to slow the sinus rate, whereas L-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NAME</z:e> and <z:chebi fb="0" ids="52289">wortmannin</z:chebi> abolished this effect </plain></SENT>
<SENT sid="13" pm="."><plain>CONCLUSION: The anti-arrhythmic effects of LLVNS involve the PI3K/NO signaling pathway </plain></SENT>
</text></document>